Cannabis stocks fell Tuesday, as analysts weighing in on Canopy Growth’s new chief executive took a cautious stance, highlighting the continuing challenges facing the company and the broader sector.
“We have harped on some of Canopy’s spending items that seem excessive: 1) equity comp greater than revenue; 2) G&A greater than revenue; and 3) inventory levels which likely don’t match the demand curve,” Kirk wrote in a note to clients. “We expect that Klein will move quickly to pursue profitability within Canopy, with an overriding focus on this metric,” Hundley wrote in a note. “Canopy has burned $800MM in cumulative funds over the past two quarters, driving a cumulative adjusted Ebitda loss of almost $250MM.
Last week, AgMedica Bioscience acknowledged a “liquidity crisis” that requires “immediate interim financing” to implement a restructuring. Wayland MRRCF, -40.29%, meanwhile, filed for creditor protection. Aleafia Health ALEAF, -0.61% ALEF, -3.03% was flat, Hexo HEXO, -4.37% HEXO, -4.95% was down 3.9% and Organigram OGI, -4.09% was down 3.4%.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: CNBC - 🏆 12. / 72 続きを読む »
ソース: CNBC - 🏆 12. / 72 続きを読む »